-
Something wrong with this record ?
Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor
K. Trtková, L. Pašková, N. Matiješčuková, Z. Kolář
Language English Country Netherlands
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
Grant support
NR9475
MZ0
CEP Register
NS10262
MZ0
CEP Register
Digital library NLK
Full text - Article
Full text - Article
Source
Source
NLK
Medline Complete (EBSCOhost)
from 2005-01-01 to 9 months ago
PubMed
21178266
DOI
10.3233/cbm-2010-0150
Knihovny.cz E-resources
- MeSH
- Receptors, Androgen genetics metabolism MeSH
- Butyrates metabolism pharmacology therapeutic use MeSH
- Time Factors MeSH
- Histone Deacetylase 2 metabolism MeSH
- Histone Deacetylases metabolism MeSH
- Immunoprecipitation MeSH
- Histone Deacetylase Inhibitors therapeutic use MeSH
- Nuclear Receptor Co-Repressor 2 genetics metabolism MeSH
- Hydroxamic Acids metabolism pharmacology therapeutic use MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms drug therapy genetics metabolism MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Protein Binding genetics MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
Signaling through the androgen receptor (AR) plays a critical role in prostate cancer progression. The AR is a classical nuclear receptor (NR) providing a link between signaling molecule and transcription response. Histone deacetylase inhibitors (HDACI) have antiproliferative and proapoptotic effects on prostate cancer cells and their implication in silence AR signaling may have potential therapeutic use. We aimed to study the inhibitory effects of the corepressor SMRT (Silencing Mediator for Retinoid and Thyroid hormone receptors) which forms a complex together with nuclear receptor corepressor (N-CoR) and with histone deacetylase 3 (HDAC3) on AR activity. The androgen-sensitive prostate cancer cell line LNCaP and androgen-insensitive prostate cancer cell line C4-2 both AR-positive, and androgen-insensitive DU145 and PC3 prostate cancer cell lines were treated with two HDACIs, sodium butyrate (NaB) and/or trichostatin A (TSA). We amplified immunoprecipitated DNA by conventional PCR and in the following step we used the chromatin immunoprecipitation (ChIP) analysis coupled with quantitative PCR for monitoring NaB induced formation of AR-SMRT/N-CoR complex binding on the PSA promoter. The co-immunoprecipitation assay revealed increase in AR-SMRT formation in NaB treated cells. Simultaneously, the Western blot analysis showed a significant decrease in AR protein expression. Furthermore, we estimated the reduced presence of HDAC2 and HDAC3 proteins by NaB and TSA treatment in AR-negative DU145 cell line. In conclusion, the inhibitory effect of NaB on AR gene expression seems to be specific and unique for prostate cancer AR-positive cell lines and corresponds with its ability to stimulate AR-SMRT complex formation. We suggest that AR and SMRT/N-CoR corepressors may form a stable complex in vitro and NaB may facilitate the interaction between AR nuclear steroid receptor and SMRT corepressor protein.
Formation of AR-SMRT complex and its binding to PSA promoter in prostate cancer cells treated with natural histone deacetylases inhibitor
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027189
- 003
- CZ-PrNML
- 005
- 20160408164106.0
- 007
- ta
- 008
- 120816s2010 ne f 000 0eng||
- 009
- AR
- 024 7_
- $a 10.3233/cbm-2010-0150 $2 doi
- 035 __
- $a (PubMed)21178266
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Smešný Trtková, Kateřina, $u Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. trtkova@post.cz $d 1965- $7 xx0143535
- 245 10
- $a Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor / $c K. Trtková, L. Pašková, N. Matiješčuková, Z. Kolář
- 246 33
- $a Formation of AR-SMRT complex and its binding to PSA promoter in prostate cancer cells treated with natural histone deacetylases inhibitor
- 520 9_
- $a Signaling through the androgen receptor (AR) plays a critical role in prostate cancer progression. The AR is a classical nuclear receptor (NR) providing a link between signaling molecule and transcription response. Histone deacetylase inhibitors (HDACI) have antiproliferative and proapoptotic effects on prostate cancer cells and their implication in silence AR signaling may have potential therapeutic use. We aimed to study the inhibitory effects of the corepressor SMRT (Silencing Mediator for Retinoid and Thyroid hormone receptors) which forms a complex together with nuclear receptor corepressor (N-CoR) and with histone deacetylase 3 (HDAC3) on AR activity. The androgen-sensitive prostate cancer cell line LNCaP and androgen-insensitive prostate cancer cell line C4-2 both AR-positive, and androgen-insensitive DU145 and PC3 prostate cancer cell lines were treated with two HDACIs, sodium butyrate (NaB) and/or trichostatin A (TSA). We amplified immunoprecipitated DNA by conventional PCR and in the following step we used the chromatin immunoprecipitation (ChIP) analysis coupled with quantitative PCR for monitoring NaB induced formation of AR-SMRT/N-CoR complex binding on the PSA promoter. The co-immunoprecipitation assay revealed increase in AR-SMRT formation in NaB treated cells. Simultaneously, the Western blot analysis showed a significant decrease in AR protein expression. Furthermore, we estimated the reduced presence of HDAC2 and HDAC3 proteins by NaB and TSA treatment in AR-negative DU145 cell line. In conclusion, the inhibitory effect of NaB on AR gene expression seems to be specific and unique for prostate cancer AR-positive cell lines and corresponds with its ability to stimulate AR-SMRT complex formation. We suggest that AR and SMRT/N-CoR corepressors may form a stable complex in vitro and NaB may facilitate the interaction between AR nuclear steroid receptor and SMRT corepressor protein.
- 650 _2
- $a butyráty $x metabolismus $x farmakologie $x terapeutické užití $7 D002087
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a histondeacetylasa 2 $x metabolismus $7 D056464
- 650 _2
- $a inhibitory histondeacetylas $x terapeutické užití $7 D056572
- 650 _2
- $a histondeacetylasy $x metabolismus $7 D006655
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kyseliny hydroxamové $x metabolismus $x farmakologie $x terapeutické užití $7 D006877
- 650 _2
- $a imunoprecipitace $7 D047468
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a korepresor 2 jaderného receptoru $x genetika $x metabolismus $7 D056985
- 650 _2
- $a nádory prostaty $x farmakoterapie $x genetika $x metabolismus $7 D011471
- 650 _2
- $a vazba proteinů $x genetika $7 D011485
- 650 _2
- $a androgenní receptory $x genetika $x metabolismus $7 D011944
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pašková, Lenka $u Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $7 xx0138057
- 700 1_
- $a Matiješčuková, Natálie $u Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Kolář, Zdeněk, $u Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $d 1953- $7 jn20000710256
- 773 0_
- $w MED00173146 $t Cancer biomarkers section A of Disease markers $x 1875-8592 $g Roč. 7, č. 2 (2010), s. 79-90
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21178266 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160408163828 $b ABA008
- 999 __
- $a ok $b bmc $g 949231 $s 784535
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 7 $c 2 $d 79-90 $i 1875-8592 $m Disease markers. Section A, Cancer Biomarkers $n Cancer Biomark $x MED00173146
- GRA __
- $a NR9475 $p MZ0
- GRA __
- $a NS10262 $p MZ0
- LZP __
- $b NLK112 $a Pubmed-20120816/11/02